Morphine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Morphine: Myofascial pain syndrome
One-Sentence Summary
Morphine is an opioid analgesic that acts mainly on mu-opioid receptors. The TxGNN model predicts a possible role in myofascial pain syndrome, but no registered clinical trials and no publications that directly test morphine in this condition were found. The evidence level is therefore L5, and the recommendation is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Myofascial pain syndrome |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Morphine is a mu-opioid receptor agonist with well-established analgesic activity, so a link to chronic musculoskeletal pain is plausible in principle.
The retrieved literature does not support the link directly. The papers cover perioperative analgesia, opioid use in jaw-joint pain, descriptive series of other pain syndromes, and animal pain models. Only one randomised trial involves morphine, as an additive to local anaesthetic infiltration during spinal fusion surgery, which is postoperative pain rather than myofascial pain syndrome.
Opioids are not a standard therapy for myofascial pain. Long-term use carries risks of tolerance, opioid-induced hyperalgesia and dependence. The high TxGNN score reflects a model-based association, not clinical proof.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of these publications tests morphine as a treatment for myofascial pain syndrome.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41664327 | 2026 | Randomised controlled trial | Asian Spine J | Dexmedetomidine plus morphine compared with plain ropivacaine for myofascial infiltration in thoracolumbar spinal fusion. This is a surgical analgesia setting, not myofascial pain syndrome. |
| 35066974 | 2022 | Retrospective cohort | Pain Pract | A structured stretching programme for myofascial pain in “legacy pain” patients, assessed for pain resolution and opioid usage. |
| 39793344 | 2025 | Clinical study | Eur J Obstet Gynecol Reprod Biol | Pudendal nerve block for perioperative pain after onabotulinumtoxinA injection for myofascial pelvic pain. Morphine is not the intervention. |
| 21419546 | 2011 | Review / commentary | J Oral Maxillofac Surg | Long-term opioid use in temporomandibular joint dysfunction can be neither supported nor refuted on current evidence. |
| 16713811 | 2006 | Clinical practice report | J Oral Maxillofac Surg | Arthrocentesis followed by intra-articular morphine infusion for refractory jaw-joint pain. |
| 16967674 | 2006 | Review | J Calif Dent Assoc | Use of oral medications, infusions and injections in the differential diagnosis of orofacial pain. |
| 21691691 | 2011 | Descriptive study | Rev Assoc Med Bras | Therapeutic approach in 56 patients with failed back surgery pain syndrome. |
| 17870625 | 2008 | Randomised trial | Eur J Pain | Epidural analgesia (bupivacaine and morphine) compared with intercostal nerve cryoanalgesia for post-thoracotomy pain. |
| 15176410 | 2004 | Case report | Nervenarzt | Long-term botulinum toxin A injections into stump muscle trigger points for phantom and stump pain. |
| 7478690 | 1995 | Animal study | Pain | Rat ureteral calculosis model of visceral pain and its relationship with referred lumbar muscle hyperalgesia. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10858L | Morphine Juno | Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL | Not available in the data compiled for this report |
Safety Considerations
- Drug Interactions (major): Fentanyl, dihydrocodeine, codeine, tramadol, butalbital, dichloralphenazone, alprazolam and ethanol are rated Major. Most are additive central nervous system and respiratory depressants. Many moderate-level interactions are also recorded, for example with chlorpheniramine, cetirizine, nifedipine, hydrochlorothiazide and metformin.
- Class-level concerns relevant to this prediction: Long-term opioid use carries risks of tolerance, opioid-induced hyperalgesia, dependence and respiratory depression.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L5. No clinical trial or publication tests morphine in myofascial pain syndrome, and the one randomised trial involving morphine concerns postoperative pain after spinal fusion. Opioids are not a standard therapy for myofascial pain, and their safety profile in chronic musculoskeletal pain is unfavourable.
To proceed, the following is needed:
- Mechanism of action data and a clear rationale for opioid use in myofascial pain
- Controlled clinical studies of morphine, or other opioids, in myofascial pain syndrome
- A risk-benefit assessment covering tolerance, hyperalgesia, dependence and respiratory depression
- Review of the TGA-approved Product Information for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.